Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis

Joint Bone Spine

Volumn 77, Issue 6, 2010, Pages 558-563

  Maillefert, Jean Francis ^a   Puéchal, Xavier ^b   Falgarone, Géraldine ^c   Lizard, Gérard ^d   Ornetti, Paul ^a   Solau, Elisabeth ^e   Legré, Virginie ^f   Lioté, Frédéric ^g   Sibilia, Jean ^h   Morel, Jacques ⁱ   Maynadié, Marc ^j  

^a HÔPITAL DU BOCAGE   (France)

^b Le Mans General Hospital   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e Poitiers University Hospital   (France)

^f Public Hospitals Marseille   (France)

^g INSERM   (France)

^h Department of Rheumatology   (France)

ⁱ LAPEYRONIE HOSPITAL   (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Cytometric bead arrays; Disease modifying drugs; Efficacy; Methotrexate; Multidrug resistance; Prediction; Rheumatoid arthritis; Serum TNF ; Treatment

Indexed keywords

GOLD SALT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DEMOGRAPHY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; JOINTS; LEUKOCYTES, MONONUCLEAR; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649904426     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.02.018     Document Type: Article

References (40)

1. O'Dell J.R., Haire C.E., Erikson N., et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
2. Mottonen R., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999, 353:1568-1573.
3. Boers M., Verhoeven A.C., Markusse H.M., et al. Randomised comparison of step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-318.
4. O'Dell J.R. Treating rheumatoid arthritis early: a window of opportunity?. Arthritis Rheum 2002, 46:283-285.
5. Landewé R.B.M., Boers M., Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention. Arthritis Rheum 2002, 46:347-356.
6. Genovese M.C., Bathon J.M., Martin R.W., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcome. Arthritis Rheum 2002, 46:1443-1450.
7. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
8. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007, 146:406-415.
9. Combe B. Should patients with recent-onset polyarthritis receive aggressive treatment?. Joint Bone Spine 2004, 71:475-480.
10. Gossec L., Dougados M., Goupille P., et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004, 63:675-680.
11. Verstappen S.M., van Albada-Kuipers G.A., Bijlsma J.W., et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005, 64:38-43. Utrecht Rheumatoid Arthritis Cohort Study Group (SRU).
12. Smolen J.S., Sokka T., Pincus T., et al. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003, 21(Suppl. 31):S209-S210.
13. Hider S.L., Buckley C., Silman A.J., et al. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol 2005, 32:11-16.
14. Anderson J.J., Wells G., Verhoeven A.C., et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000, 43:22-29.
15. Morgan C., Lunt M., Brightwell H., et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 2003, 62:15-19.
16. Capell H.A., Porter D.R., Madhok R., et al. Second line (disease modifying) treatment in rheumatoid arthritis. Which drug for which patient?. Ann Rheum Dis 1993, 52:423-428.
17. Wolfe F., Cathey M.A. The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991, 18:973-977.
18. Goëb V., Jouen F., Gilbert D. Diagnostic and prognostic usefulness of antibodies to citrullinated peptides. Joint Bone Spine 2009, 76:343-349.
19. O'Dell J.R., Nepom B.S., Haire C., et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998, 57:209-213.
20. Pham T., Fautrel B., Gottenberg J.-E., et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide developed by the Rheumatic Diseases & Inflammation Group (club rhumatismes et inflammation, CRI) of the French Society for Rheumatology (société française de rhumatologie, SFR). Joint Bone Spine 2008, 75(Suppl. 1):S2-S99.
21. Ranganathan P., Eisen S., Yokoyama W.M., et al. Will pharmacogenomics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?. Ann Rheum Dis 2003, 62:4-9.
22. Wolf J., Stranzl T., Filipits M., et al. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:564-568.
23. Wessels J.A., Kooloos W.M., De Jonge R., et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006, 54:2830-2839.
24. Le Loët X., Berthelot J.M., Cantagrel A., et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006, 65:45-50.
25. Prunet C., Montange T., Véjux A., et al. Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. Cytometry A 2006, 69:359-373.
26. van der Heijden J.W., Dijkmans B.A.C., Scheper R.J., et al. Drud insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat Clin Pract Rheumatol 2007, 3:26-34.
27. Llorente L., Richaud-Patin Y., Díaz-Borjón A., et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders Part I: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000, 67:30-39.
28. Yudoh K., Matsuno H., Nakazawa F., et al. Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum 1999, 42:2014-2015.
29. Tsujimura S., Saito K., Nawata M., et al. Overcoming drug resistance induced by P- Glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2008, 67:380-388.
30. Hider S.L., Hoggard P., Khoo S., et al. Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer. Arthritis Rheum 2005, 52:670-678.
31. Rudwaleit M., Yin Z., Siegert S., et al. Response to treatment to methotrexate in early rheumatoid arthritis is associated with a decrease of T cells derived tumour necrosis factor a, increase of interleukine 10, and predicted by the initial concentration of interleukine 4. Ann Rheum Dis 2000, 59:311-314.
32. Gerli R., Bistoni O., Lunardi C., et al. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatology 1999, 38:1282-1284.
33. Seitz M., Zwicker M., Wider B. Enhanced in vitro induced production of interleukine 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J Rheumatol 2001, 28:496-501.
34. Seitz M., Zwicker M., Villiger P.M. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American College of Rheumatology response groups to methotrexate. J Rheumatol 2003, 30:28-35.
35. Marotte H., Arnaud B., Diasparra J., et al. Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at - 308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor. Arthritis Rheum 2008, 58:1258-1263.
36. Rooney T., Roux-Lombard P., Veale D.J., et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression Analysis of a proof-of-concept randomized clinical trial of cytokine blockade. Ann Rheum Dis. 2009, [Epub ahead of print].
37. Baggott J.E., Morgan S.L. Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum 2009, 60:2257-2261.
38. van der Woude D., Young A., Jayakumar K., et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009, 60:2262-2271.
39. Hider S.L., Silman A.J., Thomson W., et al. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?. Ann Rheum Dis 2009, 69:57-62.
40. Wessels J.A., van der Kooij S.M., le Cessie S., et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007, 56:1765-1775. Pharmacogenetics Collaborative Research Group.